Synthetisches Erythropoetin – neue Perspektiven für Biologics?

Author： Minkner Robert   Möller Moritz   Schneegans Nicola   Wittstock Ute  

Publisher： Govi-Verlag

ISSN： 2195-2175

Source： PHARMAKON, Vol.2, Iss.4, 2014-07, pp. : 241-243

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

NOAK – Neue orale Antikoagulantien Studienübersicht, substanzspezifische Unterschiede und Hinweise für die Praxis

By Lipp Hans-Peter  

PZ PRISMA, Vol. 21, Iss. 2, 2014-04 ,pp. : 97-108

Govi-Verlag

Access to resources Recommend Favorite

Medizin: KRAS-Inhibitoren für die Krebstherapie – neue Strategie, aber auch viele Fragen

By Holzgrabe Ulrike  

PHARMAKON, Vol. 1, Iss. 5, 2013-09 ,pp. : 375-375

Govi-Verlag

Access to resources Recommend Favorite

Preclinical development of therapeutic biologics

By Baumann Andreas  

Expert Opinion on Drug Discovery, Vol. 3, Iss. 3, 2008-03 ,pp. : 289-297

Informa Healthcare

Access to resources Recommend Favorite

Toxicity as a result of immunostimulation by biologics

By Gribble Elizabeth J   Sivakumar Pallavar V   Ponce Rafael A   Hughes Steven D  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 3, Iss. 2, 2007-04 ,pp. : 209-234

Informa Healthcare

Access to resources Recommend Favorite